Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults

Trial Profile

A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VBI 2902 (Primary) ; Aluminium phosphate
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Proof of concept
  • Sponsors VBI Vaccines

Most Recent Events

  • 14 Feb 2023 Status changed from active, no longer recruiting to completed.
  • 18 Jul 2022 Number of treatment arms decreased from 6 to 5, by the removal of Experimental: Phase 1b, Group G6 arm.
  • 18 Jul 2022 Planned End Date changed from 1 Nov 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top